A phase II study of dasatinib in relapsed and-refractory chronic lymphocytic leukemia (CLL/SLL)

被引：6
|
作者：
Amrein, Philip C. [1 ]
Attar, Eyal C. [1 ]
Takvorian, Tak [1 ]
Hochberg, Ephraim P. [1 ]
Ballen, Karen [1 ]
Zabrieh, David [2 ]
Brown, Jennifer R. [2 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Dana Farber Canc Inst, Boston, MA USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.3126.3126
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3126
引用
收藏
页码：920A / 920A
页数：1
相关论文
共 50 条
  • [31] A phase II study of MOR208 plus idelalisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (MIRACLE).
    Wendtner, Clemens-Martin
    Byrd, John C.
    Eichhorst, Barbara
    Foa, Robin
    Hallek, Michael
    Hillmen, Peter
    Jager, Ulrich
    Jurczak, Wojciech
    Kelemen, Peter
    Laribi, Kamel
    Munir, Talha
    Staber, Philipp B.
    Stilgenbauer, Stephan
    Woyach, Jennifer Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] ALPINE: Phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
    Hillmen, Peter
    Brown, Jennifer R.
    Byrd, John C.
    Eichhorst, Barbara
    Lamanna, Nicole
    O'Brien, Susan Mary
    Qiu, Lugui
    Paik, Jason C.
    Hilger, James D.
    Huang, Jane
    Tam, Constantine S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] Phase I/II study of rituxan in chronic lymphocytic leukemia (CLL).
    O'Brien, S
    Freireich, E
    Andreeff, M
    Lerner, S
    Keating, M
    BLOOD, 1998, 92 (10) : 105A - 105A
  • [34] ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
    Wilson, W.
    O'Connor, O. O.
    Roberts, A. W.
    Czuczman, M.
    Brown, J.
    Xiong, H.
    Xiong, H.
    Chiu, Y.
    Krivoshik, A.
    Enschede, S.
    Humerickhouse, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [35] Pre-Clinical and Interim Results of a Phase II Trial of Perifosine In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    Friedman, Daphne R.
    Davis, Patricia H.
    Lanasa, Mark C.
    Moore, Joseph O.
    Gockerman, Jon P.
    Nelson, Taylor
    Bond, Karen M.
    Jiang, Ning
    Davis, Evan D.
    Allgood, Sallie D.
    Chen, Youwei
    Sportelli, Peter
    Weinberg, J. Brice
    BLOOD, 2010, 116 (21) : 768 - 769
  • [36] Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)
    Wendtner, Clemens
    Hillmen, Peter
    Mahadevan, Daruka
    Stilgenbauer, Stephan
    Uharek, Lutz
    Coutre, Steven
    Frankfurt, Olga
    Bloor, Adrian
    Bosch, Francesc
    Furman, Richard R.
    Kimby, Eva
    Gribben, John G.
    Gobbi, Marco
    Dreisbach, Luke
    Hurd, David Duane
    Sekeres, Mikkael A.
    Ferrajoli, Alessandra
    Shah, Sheetal
    Zhang, Jennie
    de Parseval, Laure Moutouh
    Chanan-Khan, Asher A.
    BLOOD, 2010, 116 (21) : 591 - 592
  • [37] Phase II trial of the combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)
    Falchi, Lorenzo
    Keating, Michael J.
    Badoux, Xavier C.
    Wierda, William G.
    O'Brien, Susan Mary
    Smith, Susan C.
    Wen, Sijin
    Kantarjian, Hagop
    Ferrajoli, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Brown, Jennifer R.
    Hillmen, Peter
    Eichhorst, Barbara
    Lamanna, Nicole
    O'Brien, Susan
    Tam, Constantine S.
    Qiu, Lugui
    Kazmierczak, Maciej
    Zhou, Keshu
    Simkovic, Martin
    Mayer, Jiri
    Gillespie-Twardy, Amanda
    Shadman, Mazyar
    Ferrajoli, Alessandra
    Ganly, Peter S.
    Weinkove, Robert
    Salmi, Tommi
    Wu, Kenneth
    Novotny, William
    Jurczak, Wojciech
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S266 - S266
  • [39] Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
    Badoux, Xavier C.
    Keating, Michael J.
    Wen, Sijin
    Wierda, William G.
    O'Brien, Susan M.
    Faderl, Stefan
    Sargent, Rachel
    Burger, Jan A.
    Ferrajoli, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (05) : 584 - 591
  • [40] Are chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) the same disease?
    Keating, M
    McLaughlin, P
    Tsimberidou, A
    O'Brien, S
    ANNALS OF ONCOLOGY, 2005, 16 : 46 - 47
12345